ACTRN12617001578392已完成2 期
Efficacy and Safety of Deferiprone in Treatment-Naïve and Non-Treatment-Naïve Patients with Parkinson’s Disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 79 Years（—）
- 性别
- All
入选标准
- •Main inclusion criteria (all patients):
- •1. Male or female aged 18 to < 80 years
- •2. Parkinson’s disease diagnosed according to UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria and based on the presence of at least two of the three cardinal features of the disease (rest tremor, bradykinesia, and rigidity). If rest tremor is not present, patients must have unilateral onset of symptoms.
- •3. Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L (greater than or equal to 1.0 x 10^9/L for Black population)
- •Inclusion criterion for treatment-naïve patients only:
- •1. At an early stage of the disease, without motor fluctuations
- •Inclusion criteria for non-treatment-naïve patients only:
- •1. On a stable dose for at least 3 months prior to the screening visit of any of the following treatments at an L-dopa equivalent total daily dose of up to 600 mg:
- •- Dopaminergic agonist alone
- •- L-dopa alone
- •- Combination therapy with dopaminergic agonist and L-dopa
- •- Rasagiline
- •2. At an early stage of the disease, without motor fluctuations and/or L-dopa–induced dyskinesia
排除标准
- •Main exclusion criteria (all patients):
- •1. Diagnosis of Parkinson’s disease more than 3 years prior to screening visit
- •2. Hoehn and Yahr stage greater than or equal to 3 in the Off” state, indicating the need for walking assistance in the absence of treatment.
- •3. Atypical or secondary Parkinsonism without dopa-sensitivity (e.g., vascular parkinsonism, supranuclear palsy, multisystem atrophy)
- •4. Progressing Axis I psychiatric disorders (psychosis, hallucinations, compulsive disorders, substance addiction, bipolar disorder, severe depression, anxiety) as assessed in a semi-structured interview in accordance with the Diagnostic and Statistical Manual of Mental Disorders
- •5. Current treatment with bromocriptine
- •6. Current treatment with coenzyme Q10 or idebenone. (Patients who are on these medications but stop taking them at least 2 weeks prior to baseline may be enrolled.)
- •7. Current use of a Deep Brain Stimulation (DBS) system. (Patients who previously had a DBS system but have had it removed may be enrolled.)
- •Exclusion criteria for treatment-naïve patients only:
- •1. Previous or current treatment with antiparkinsonian medication, or likely to require such medication over the duration of the trial
- •2. Current treatment with coenzyme Q10 at any dosage. (Patients who are on this medication at a dosage <300 mg/day but stop taking it at least 2 weeks prior to the first dose of study medication may be enrolled.)
- •Exclusion criteria for non-treatment-naïve patients only:
- •1. Not stabilized in terms of the current antiparkinsonian therapeutic regimen, and likely to require any change in dopamine therapy over the duration of the trial
- •2. Current treatment with any antiparkinsonian drug other than those listed in the inclusion criteria
研究者
相似试验
进行中（未招募）
1 期
An international open label trial of deferiprone in patients with iron storage brain disorders - an extension to TIRCON2012V1 (a randomised controlled trial of deferiprone in patients with iron storage brain disorders).EUCTR2014-001427-79-GBApoPharma Inc89
进行中（未招募）
1 期
An 18-month extension of an international trial of deferiprone in patients with iron storage brain disordersEUCTR2014-001427-79-DEApoPharma Inc.90
进行中（未招募）
1 期
An 18-month extension of an international trial of deferiprone in patients with iron storage brain disordersPantothenate Kinase-Associated Neurodegeneration (PKAN)MedDRA version: 21.1Level: PTClassification code 10053643Term: Neurodegenerative disorderSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-001427-79-ITAPOTEX EUROPE B.V.68
招募中
3 期
Effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)Patients with Covid 19.Covid 19U07.01IRCT20180114038350N3Sanandaj University of Medical Sciences80
已完成
不适用
Treatment effect of deferiprone and desferrioxamine in beta thalassemia majorIRCT138810203032N1Mazndaran University of Medical Science100